A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms MIURCCEVERO
- 12 Oct 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
- 12 Oct 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 17 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as per Clinicaltrial.gov record.